KTTAW Stock Overview: Comprehensive Insights on Pasithea Therapeutics Corp. Shares

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

Altman Z Score -3.61
Piotroski Score 4.00
Grade N/A

Company brief: Pasithea Therapeutics Corp. (KTTAW)

Sector Healthcare
Industry Biotechnology
CEO Dr. Tiago Reis Marques M.D., Ph.D.
Website http://pasitheaclinics.com
Country US
Employees (FY) 8
Founded 09/15/2021
ISIN US70261F1113

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.

Price Target and Rating

Average Stock Price Target $0.00
High Stock Price Target $0.00
Low Stock Price Target $0.00
Potential Upside/Downside N/A
Consensus Rating Sell
Rating Score (0-4) N/A
Research Coverage N/A

Profitability

EPS (Most Recent Fiscal Year) $0.00
Trailing P/E Ratio N/A
Forward P/E Ratio N/A
P/E Growth N/A
Net Income $-15,961,658

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Pasithea Therapeutics Corp. (KTTAW) Stock Price, News & Analysis

Stock Score/grades

Company brief: Pasithea Therapeutics Corp. (KTTAW)

Price Target and Rating

Profitability

Key Stats

Select an alert type

Setup alert

Log In

Email Verification

Welcome to StockNews!

Create Your Account

Email Verification